Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 18/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 7/20 | 0.45 |
| ▸ | CCR2 | P41597 | 6/20 | 0.45 |
| ▸ | CNR1 | P21554 | 2/20 | 0.44 |
| ▸ | CNR2 | P34972 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13578257 | 0.85 | ROCK2 (0.46) | ROCK2ROCK1CCR2 | |
| SCHEMBL4330441 | 0.85 | CNR2 (0.61) | ROCK2ROCK1CNR1CNR2 | |
| SCHEMBL4323408 | 0.85 | CNR1 (0.52) | ROCK2ROCK1CNR1CNR2 | |
| SCHEMBL4323411 | 0.85 | CNR1 (0.61) | ROCK2ROCK1CNR1CNR2 | |
| SCHEMBL4327410 | 0.83 | CNR1 (0.47) | CNR1CNR2 | |
| SCHEMBL4333479 | 0.80 | CNR1 (0.52) | CNR1CNR2 | |
| SCHEMBL4319768 | 0.78 | CNR1 (0.55) | CNR1CNR2 | |
| SCHEMBL4328685 | 0.78 | CNR1 (0.48) | CNR1CNR2 | |
| SCHEMBL4323159 | 0.76 | CNR2 (0.74) | CNR1CNR2 | |
| SCHEMBL13578116 | 0.76 | CNR2 (0.48) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325936-A1 | IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | MERCK & CO., INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090325936-A1 | IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | MERCK & CO., INC. | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325936-A1 | IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | CNR2, CNR1, TRPV1 | ROCK2 2727/4885ROCK1 2814/4885CCR2 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.